GC Biopharma USA
GC Biopharma USA Inc. is a Teaneck, NJ-based biopharmaceutical subsidiary that commercializes ALYGLO, an FDA-approved plasma-derived IVIG therapy for primary immunodeficiency, using its proprietary G-XI™ manufacturing technology, selling to hospitals, immunology clinics, and specialist prescribers across North America.
- Company typePrivate
- Founded2018
- HeadquartersTeaneck, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What GC Biopharma USA does
GC Biopharma USA Inc. is a US-incorporated biopharmaceutical subsidiary headquartered in Teaneck, New Jersey, that commercializes plasma-derived immunoglobulin therapies in the North American market. The company's flagship product, ALYGLO (immune globulin intravenous, human-icp), is an FDA-approved intravenous immunoglobulin (IVIG) therapy for the treatment of primary immunodeficiency, launched commercially in November 2024 following regulatory approval. ALYGLO is manufactured using the company's proprietary G-XI™ Technology, a plasma fractionation and process platform that the company positions as a differentiator in product viscosity, process optimization, and clinical performance relative to competing IVIG products.
The company pursues an enterprise field sales go-to-market motion, selling through pharmaceutical distribution channels to hospitals, immunology clinics, and specialist healthcare providers who prescribe and administer IVIG therapies. Revenue is generated through one-time product sales (specialty pharma unit economics), though specific pricing and contract terms are not publicly disclosed. Its customer base spans two primary segments: individual patients with primary immunodeficiency disorders requiring regular immunoglobulin replacement, and the institutional prescribers (immunologists and treatment centers) who administer care. The company has stated geographic focus on North America as its largest market and has identified Asia-Pacific as the fastest-growing region for immunoglobulin therapies, signaling international expansion intent.
Commercially, GC Biopharma USA builds clinical credibility through conference engagement (2025 IgNS Annual Meeting symposium, CIIC Fall Conference partnership) and scientific publication support (2025 IgNS Patient 360 Longitudinal Survey). The company is privately held, operates with an 11–50 employee footprint, and reports no parent company, funding rounds, or disclosed financial metrics in the available data. The core revenue driver is a single recently launched product, which is both the principal asset and the principal concentration risk.
GC Biopharma USA firmographics
Firmographics- Name
- GC Biopharma USA
- Legal name
- GC Biopharma USA Inc.
- Website
- https://gcbiopharma.us
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GC Biopharma USA Inc. is a Teaneck, NJ-based biopharmaceutical subsidiary that commercializes ALYGLO, an FDA-approved plasma-derived IVIG therapy for primary immunodeficiency, using its proprietary G-XI™ manufacturing technology, selling to hospitals, immunology clinics, and specialist prescribers across North America.
- Ownership category
- akta.pro rank
Where GC Biopharma USA is headquartered
LocationHeadquarters
- HQ city
- Teaneck
- HQ country
- United States
- HQ region
- North America
Markets served
GC Biopharma USA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical product sales: GC Biopharma USA generates revenue through the sale of FDA-approved plasma-derived biological products, primarily ALYGLO for immunodeficiency treatment. The company operates in the specialty pharmaceutical sector targeting healthcare providers and patients requiring immunoglobulin therapy.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
GC Biopharma USA product offering
Product offeringCore offering
GC Biopharma USA manufactures and distributes ALYGLO, an FDA-approved intravenous immunoglobulin (IVIG) therapy indicated for primary immunodeficiency disorders. The product is produced using the company's proprietary G-XI™ plasma-derived manufacturing technology and sold through pharmaceutical distribution channels to healthcare providers, hospitals, and immunology treatment centers.
Product overview
GC Biopharma USA is a pharmaceutical company specializing in plasma-derived immunoglobulin therapies. Their core product is ALYGLO (IVIG therapy) for immunodeficiency treatment, which utilizes the proprietary G-XI™ Technology platform. The company focuses on advancing IVIG treatment through manufacturing innovation, clinical research, and patient care programs.
Differentiator
Problem solved
Functional benefit
Brands
- ALYGLO with G-XI Technology: IVIG product featuring proprietary G-XI Technology for plasma-derived immunoglobulin therapy.
Products and services
- ALYGLO ALYGLO is an FDA-approved intravenous immunoglobulin (IVIG) therapy for treating primary immunodeficiency in patients. It utilizes GC Biopharma's proprietary G-XI™ Technology and is sold to healthcare providers, hospitals, and immunology treatment centers in North America.
Quantifiable outcome
- Rising prevalence of immune disorders drives demand for immunoglobulin therapies
Companies that use GC Biopharma USA
Customer profileSegments2 records
Ideal customer profiles1 record
GC Biopharma USA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
GC Biopharma USA partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CIIC (Clinical Immunology Innovation Conference)minorGC Biopharma participated as the exclusive Science to Solutions Partner at the 2025 CIIC Fall Conference. The partnership enabled the company to showcase its IVIG product pipeline and research initiatives, highlighting advancements in plasma-derived immunoglobulin therapies including ALYGLO with G-XI Technology.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
GC Biopharma USA competitors and assessment
Company assessmentDirect peers
- Biotest AG: Plasma protein specialist developing and marketing IVIG products (e.g., Intratect) in US and international markets. Direct competitor in plasma-derived IVIG for immunodeficiency indications.
- Octapharma: Privately held global plasma fractionator with IVIG products (e.g., Octagam) marketed in the US. Directly comparable as a plasma-derived IVIG manufacturer targeting the same primary immunodeficiency patient population.
- Kedrion Biopharma: Plasma-derived therapies company marketing IVIG products (e.g., Gammaked, Gamunex-C distribution rights) in the US. Direct competitor to GC Biopharma USA in the plasma-derived IVIG space.
- ADMA Biologics: US-based commercial-stage plasma-derived biologics company marketing IVIG products (ASCENIV, BIVIGAM) for primary immunodeficiency. Closely comparable as a smaller, IVIG-focused US commercial player competing in the same indication.
- Bio Products Laboratory (BPL): Plasma-derived therapies manufacturer with US-marketed IVIG products (e.g., Gammaplex). Direct competitor in US plasma-derived IVIG for primary immunodeficiency.
Emerging players
- Kamada Ltd. Plasma-derived specialty biopharmaceutical company with IVIG and hyperimmune products commercialized in select markets. Comparable as a smaller plasma-derived player with US commercial activity overlapping with GC Biopharma USA.
Broad incumbents
- Pfizer (Panzyga): Markets Panzyga, a 10% liquid IVIG, in the US for primary immunodeficiency. Broad-incumbent IVIG competitor with significantly larger commercial reach than GC Biopharma USA.
- Grifols: Global plasma-derived therapies leader with a broad IVIG and plasma product portfolio. Directly comparable as a large-scale plasma fractionator and IVIG supplier operating in North America alongside GC Biopharma USA.
- CSL Behring: Subsidiary of CSL Limited and one of the largest global manufacturers of plasma-derived immunoglobulin therapies, including IVIG brands such as Privigen and Hizentra. Most direct large incumbent competitor to ALYGLO in the US IVIG market.
- Takeda Pharmaceutical (Plasma-Derived Therapies): Acquired Baxalta and operates a major plasma-derived therapies franchise including Gammagard, the largest IVIG franchise in the US. Comparable as a broad-incumbent IVIG competitor in the same primary immunodeficiency indication.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
GC Biopharma USA financial estimates
Financial estimateRevenue estimate
Valuation estimate
GC Biopharma USA leadership team
Management profileNumber of profiles
GC Biopharma USA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GC Biopharma USA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GC Biopharma USA
What does GC Biopharma USA do?
GC Biopharma USA manufactures and distributes ALYGLO, an FDA-approved intravenous immunoglobulin (IVIG) therapy indicated for primary immunodeficiency disorders. The product is produced using the company's proprietary G-XI™ plasma-derived manufacturing technology and sold through pharmaceutical distribution channels to healthcare providers, hospitals, and immunology treatment centers.
Is GC Biopharma USA a public or private company?
GC Biopharma USA is a private company. It is classified as corporate owned and is currently operating.
When was GC Biopharma USA founded?
GC Biopharma USA was founded in 2018. It employs 11 to 50 people.
Where is GC Biopharma USA based?
GC Biopharma USA is headquartered in Teaneck, United States, in the North America region.
How does GC Biopharma USA make money?
One revenue line is on record: pharmaceutical product sales.
Who are GC Biopharma USA's main competitors?
Direct peers on record are Biotest AG, Octapharma, Kedrion Biopharma, ADMA Biologics and Bio Products Laboratory (BPL). Kamada Ltd. is listed as an emerging player. Broad incumbents are Pfizer (Panzyga), Grifols, CSL Behring and Takeda Pharmaceutical (Plasma-Derived Therapies).
Does GC Biopharma USA have an API?
No public API is recorded for GC Biopharma USA.